Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Gynaecological cancers 1

806O - Radical hysterectomy in cervical cancer patients with intraoperatively detected positive lymph node: ABRAX multicentric retrospective cohort study (ENGOT-Cx3/CEEGOG CX2)


19 Sep 2020


Proffered Paper - Gynaecological cancers 1


Tumour Site

Cervical Cancer


David Cibula


Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276


D. Cibula1, L. Dostalek2, P. Hillemanns3, G. Scambia4, J. Persson5, F. Raspagliesi6, Z. Novak7, A. Jaeger8, M.E. Capilna9, V. Weinberger10, J. Klat11, R.L. Schmidt12, A. Lopez13, G. Scibilia14, R. Pareja15, A. Kucukmetin16, L. Kreitner17, A. El-Balat18, S. Laufhutte19, I. Runnenbaum20

Author affiliations

  • 1 Gynecologic Oncology Center, Department Of Obstetrics And Gynecology, First Faculty of Medicine, Charles University and General University Hospital, 128 08 - Prague/CZ
  • 2 Gynecologic Oncology Center, Department Of Obstetrics And Gynecology, First Faculty of Medicine, Charles University and General University Hospital, Prague/CZ
  • 3 Department Of Gynaecology And Obstetrics, Medical University Hannover, Hannover/DE
  • 4 Comprehensive Oncology Gynecology Operational Unit, Fondazione Policlinico Gemelli IRCCS, Rome/IT
  • 5 Department Of Obstetrics And Gynecology, Skane University Hospital, Lund/SE
  • 6 Struttura Complessa Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale Tumori - Milan, Milan/IT
  • 7 Department Of Gynecology, National Institute of Oncology, Budapest/HU
  • 8 Department Of Gynecology, University medical center Hamburg-Eppendorf, Hamburg/DE
  • 9 First Obstetrics And Gynecology Clinic, University of Medicine and Pharmacy Targu Mures, Targu Mures/RO
  • 10 Department Of Gynecology And Obstetrics, Faculty of Medicine, Masaryk University, Brno/CZ
  • 11 Department Of Obstetrics And Gynecology, University Hospital Ostrava, Ostrava Poruba/CZ
  • 12 Gynecologic Oncology Department, Barretos Cancer Hospital, Barretos/BR
  • 13 Department Of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima/PE
  • 14 Obstetrics And Gynecology Unit, Cannizzaro Hospital, Catania/IT
  • 15 Gynecologic Oncology, National Institute of Cancerology, Bogota/CO
  • 16 Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead/GB
  • 17 Gynecology Cancer Center, St. Franzis Hospital Munster, Munster/DE
  • 18 University Clinic Frankfurt, Goethe-University, Frankfurt/DE
  • 19 Department Of Obstetrics And Gynecology, District Hospital Altotting, Altotting/DE
  • 20 Department Of Gynecology And Reproductive Medicine, Jena University Hospital, Friedrich Schiller University, Jena/DE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 806O


The management of patients with intraoperatively detected positivity of pelvic lymph nodes (LN) remains controversial. Namely, a combination of extensive surgical dissection in the pelvis followed by pelvic radiotherapy is associated with higher morbidity. Goal of ABRAX multicentric, retrospective, cohort study was to determine whether the completion of radical hysterectomy improves oncological outcome of such patients.


A total of 515 cervical cancer patients, who intraoperatively turned to be LN positive, referred for primary surgery with a curative intent between 2005 and 2015 (stage IA-IIB, common tumour types) were retrospectively analysed in 51 institutions from 19 countries. LNs with metastasis ≥2 mm were considered positive (N1). Completion (COMPL group, n=361) or abandonment (ABAND group, n=154) of planned uterine surgery stratified the cohort in two subgroups in which oncological outcomes and major prognostic factors were evaluated. 91.4% of COMPL group underwent adjuvant chemoradiation, 100% of ABAND group were treated with primary chemoradiation.


Disease free survival reached 74% (381/515) in the whole cohort with the median follow-up of 48.9 months. Both groups (ABAND and COMPL) were balanced in main prognostic factors (tumour size, tumour type, stage of disease). No significant difference was found between the groups in the risk of recurrence (HR=1.154; p=0.446), local recurrence (HR=0.836; p=0.557), or death (HR=1.064; p=0.779). Subgroup analyses did not identify any cohort with survival benefit from radical surgery completion. Increasing FIGO stage and tumour size ≥4 cm were identified as major prognostic factors for recurrence and survival in the whole cohort.


ABRAX trial revealed that completion of radical hysterectomy in patients with intraoperative detection of positive lymph node does not improve the survival; recurrence risk is not decreased irrespective of tumour size or tumour type. Therefore, if pelvic LN involvement is diagnosed at surgery, abandonment of planned uterine procedure should be considered and the patient should be referred to definitive chemoradiation.

Clinical trial identification

NCT04037124; July 30, 2019.

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Charles University in Prague (UNCE 204065 and PROGRES Q28/LF1), and the Czech Research Council (No 16-31643A).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.